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A B S T R A C T
Paraneoplastic cerebellar degeneration (PCD), the one of the most common paraneoplastic syndromes, refer to clinical
disorders associated mostly with lung, ovarian and breast cancer, but not directly caused by the cancer or its metastases.
Pathologic finding is an extensive loss of Purkinje cells in the cerebellum. Immunohistocemicaly, the auto-antibodies on
the Purkinje cells had been detected. Clinically, PCD is characterized by sub-acutely evolving pancerebellar symptoms.
Neurological dysfunction may appear before the detection of the underlying cancer. Therefore, the surgical exploration is
necessary for the final diagnosis. The patient undergoes specific therapy. Soon, neurological status of the patient gets ir-
reparable worse. Death come usually 2–3 years after the first symptoms of the PCD occurs. Case of a 63-years old woman
with PCD as the first evidence of her cancer is reported. The patient developed brain metastases and died almost 3 years
after the first symptoms of PCD occur.
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Case Report
A 63-years-old woman, doctor in retirement, married,
mother of two children was admitted to hospital for eval-
uation of an unsteady gait, slurred speech and some oth-
ers, mostly cerebellar symptoms that had appeared a few
weeks before.
The first of her four hospitalizations followed in the
Department of Neurology, University Hospital Zagreb.
During the time she had spent in the hospital, June, 18th
– July, 11th, 2002, the detailed diagnostic procedure was
made.
In the blood analysis, a mild leukocytosis was re-
vealed (L=11.4, normal 4–10x109/L). The urine and the
biochemical analysis were nonspecific.
Multi-slice computed tomography of the abdomen and
the pelvis and gynecological ultrasound showed mostly
solid tumor mass in the left ovary, approximately 3.5x2.3
cm in the diameter with the venous type of a neo-
vascularization. No enlarged lymph-node and no ascites
were showed.
Serum cancer antigen levels were normal, except CA
125 level, an ovarian tumor marker which was 66.78
(normal 0.00–35.00 kIU/L).
Clinically, gynecological examination was normal, ac-
cording to the years of the patient. Other physical exami-
nations, including breast examination were also nega-
tive, except neurological status.
Neurological examination showed mild dysarthria,
vertical diplopia on the left gaze with evoked horizontal
nistagmus, slight ataxia on finger-to-nose and heel-to-
-shin testing; truncal ataxia, dysmetria mainly of the
lower limbs. Her gait was broad-based and unsteady. The
deep tendon reflexes were brisk and the toes were down
going, she was unable to do tandem walking.
The suspicion on the gynecologic malignant was made
and a laparoscopy in the Gynecologic Cancer Center,
University Hospital Zagreb, was performed. A mass in
the left ovary and the small, white nodule on the right
fallopian tube were found. The uterus, the right ovary
and the left fallopian tube appeared normal. No enlarged
lymph-node and no ascites were found. She underwent
bilateral salpingo-oophorectomy and the samplings of
peritoneal washings for cytology were performed.
Cytology of the peritoneal irrigation fluid was nega-
tive for malignant cells. The pathological analysis re-
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vealed stage II A ovarian serous adenocarcinoma and se-
rous adenocarcinoma of the part fimbriatic of the right
fallopian tube.
Postoperatively, the patient started intravenous im-
munoglobulin (35 mg) treatment with corticosteroids.
At 2002 year no immunoassay for detection of anti-
-Purkinje cells in Croatia was performed. In this case, we
had good reasons for suspicion on PCD. That is why our
patient was the first one that the immunoassay for detec-
tion of anti-Purkinje cells was performed.
The Western blot immuno-analysis of the serum was
positive for anti-Yo antibodies and diagnose of PCD with
the ovarian cancer was completed.
The patient started treatment with paclitaxel, 175
mg/m2 and carboplatin, AUC 5.5, 6 cycles.
After such therapy, CA 125 levels normalized (CA
125=16.10 kIU/L in October 2002, in contrast to those in
August, 2002, which was 334.00 kIU/L) and gyneco-
logical examination was adequate.
When she was discharged from the acute care hospi-
tal, the patient was under the therapy that oncologist,
neurologist, internist and psychiatrist suggested – one
year more she was taken cyclophosphamid, 100 mg/per
os, corticosteroids (Decortin, 60 mg), antiepileptic (Depa-
kine, 300 mg, Rivotril, 1 mg), antyhypertensiv (Atenolol,
12.5 mg, Kalinor 2 tbl) and psychyatric drugs (Fluzepam,
15–30 mg).
She made modest improvement in her balance during
transfers and ambulation at the end of the acute hospital
stay. Functionally, the patient required minimal assis-
tance for feeding and grooming, but needed moderate as-
sistance for all the other activities of daily living. Above
all, her functional status was minimally improved com-
pared with that at admission. Her laboratory tests were
almost normal, except mild leukocytosis.
In May of 2005 her neurological symptoms rapidly
getting worse. Physical examination showed worsening
of her ataxia, dysarthria, she became impassive and in-
continent. Head MR images showed multiple metastases
particularly in the left hemisphere of the brain. The irra-
diation therapy on the whole CNS was performed – 30
Gy/10 fractions.
For the next few weeks her condition was well. After
that period, in July 2005 she became irreparable worse.
She needed constantly assistance for all the activities of
daily living. In blood analysis the mild leukocytosis (L=
10.1) and thrombpcytopenia (T=83, normal 100–400 ´
109/L) were detected. CA 125 levels were elevated (CA
125=63.20). Her serum chemistry and liver function
showed higher levels of AST (AST=39, normal under 30
U/L), ALT (ALT=70, normal under 36 U/L), gGT (gGT=
102, normal under 35 U/L), glucose (glucose=8.2, normal
3.75–6.0 mmol/L) and lower levels of potassium (K=3.7,
normal 3.8–5.5 mmol/L).
It was clearly understood that she had to have an-
other chemotherapy, carboplatin and cyclopfosphamid,
but because of the thrombocytopenia, the chemotherapy
was delayed.
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Fig. 1. Endoscopic view of the left ovary tumor.
Fig. 2. a) Photomicrograph – histopathological findings of the
left ovary tumor.
Fig 2. b) Photomicrograph – histopathological findings of the left
ovary tumor (higher resolution).
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The patient died in July, 2005, with hepatorenal in-
sufficient and lack of the consciousness.
Discussion
Paraneoplastic neurological disorders are manifesta-
tions of an antitumor immune response. It consist of a
variety of neurological disorders like paraneoplastic en-
cephalomyelitis, PE, paraneoplastic sensory neuropathy,
PSN, paraneoplastic cerebellar degeneration, PCD, pa-
raneoplastic opsoclonus-myoclonus ataxia, POMA and
Stiffmann syndrome1–4.
Paraneoplastic disorders are characterized by the pre-
sence of neuronal auto-antibodies in patient serum. The
detection of these auto-antibodies is useful for the clini-
cians as it represents the presence of an underlying
tumor1–4.
Clinical presentation includes sensory and memory
loss, cerebellar, brainstem, motor or autonomic dysfunc-
tion, involuntary saccadic eye movements, truncal and
limbic myoclonus and ataxia4–6.
In laboratory tests, usually a mild leukocytosis is re-
vealed and higher levels of some of the serum tumor
markers with normal blood chemistry and urine analy-
sis1–3.
Tumors that have been known to initiate paraneo-
plastic disorders are lung cancer, neuroblastoma, breast,
ovarian and testicular cancers1,2.
There is a strong association among paraneoplastic
syndromes, anti-neuronal antibody specifities and the
associated tumor types. Anti-Hu antibodies have pa-
tients with lung cancer and neuroblastomas. Anti-Ri an-
tibodies have patients with breast and lung cancer. Anti-
-Yo antibodies have patients with ovarian or breast
cancer or some others gynecologic cancers1,2.
The paraneoplastic syndromes are estimated to occur
with a frequency of no more than 1% of all cancer pa-
tients, but it always indicated further investigations2.
False-positive results of presenting an auto-antibody is
not yet been reported.
The Western Blot immunoassay provides a sensitive
method for simultaneous screening and confirmation of
auto-antibodies against various neuronal antigens pres-
ent in the nucleus as well as the cytoplasm of granular
cells2. This method is in use in the Department of Immu-
nology of the University Hospital Zagreb.
The Immuno-Blot anti-neuronal antibody strips con-
tain 125, 70 and 77 kD molecular weight markers. Anti-
-Hu and anti-Ri reactions can be easily observed at 35–40
and 55 kD region respectively, anti-Yo reactions at 24–62
kD. If the specimen yields no immuno-reactivity on the
blot strip, the result should be reported as negative2,3,7.
In our patient, 2–3 weeks passed between the first
symptoms appeared and the first hospitalization in De-
partment of Neurology, University Hospital Zagreb. An-
other 7–8 weeks passed until the neurological illnesses
were excluded. From the appearance of the first neuro-
logical signs and death passed about 3 years. The patient
gets worse constantly with a period of stagnation, but no
regression of the symptoms.
The patient underwent surgical procedure, intrave-
nous immunoglobulin and corticosteroid treatment and
chemotherapy. All the time she received bedside physical
therapy and psychiatric consultation.
At 2002 year no immunoassay for detection of anti-
-Purkinje cells in Croatia was performed. In this case, we
had good reasons for suspicion on PCD. That is why our
patient was the first one that the immunoassay for detec-
tion of anti-Purkinje cells was performed.
By the western blot immunoassay, the reaction ap-
peared at 24–65 kD and the anti-Yo antibody was recog-
nized as positive. In according to the pathologic findings
of the stage II A ovarian serous adenocarcinoma and se-
rous adenocarcinoma of the part fimbriatic of the right
fallopian tube and neurological disorders, the diagnosis
of the paraneoplastic cerebellar degeneration with the
ovarian cancer was made.
It is known that in neurologically normal patient with
above mentioned cancers no anti-neuronal antibodies
were found5.
This evidence leads to questions about the factors
that cause the appearance of the anti-neuronal antibod-
ies and paraneoplastic syndromes in general.
When these mechanisms will be understood com-
pletely, the further investigations about the appropriate
treatment of the neurological symptoms will be observ-
ed. It is necessary because the present procedure, such as
surgical, immunoglobulin and chemotherapy have no in-
fluences on the neurological symptoms. The patient has
some period of getting better, but soon the neurological
symptoms getting worse and led to death in a no-con-
sciousness state of mind6. Further investigation into the
pathogenesis of paraneoplastic cerebellar degeneration
combined with earlier detection and therapy of the ma-
lignancy may offer an improved neurological prognosis in
the future.
In this case, there is another thing that has to be em-
phasized. To our best knowledge, brain metastases from
ovarian cancer are uncommon. The incidence of cerebral
metastases from epithelial ovarian cancer is 0.29%–1.3%
according to different authors8–14. Diagnosis of brain
metastases is readily made on high-resolution imaging
technology such as CT scan or MRI. There is no standard
treatment for brain metastases from ovarian cancer. The
choice of therapy is based on the location of metastases,
the presence of disease at other sites, and history of pre-
vious treatment. The array of therapies includes surgery,
radiotherapy and chemotherapy8–10. The outcomes of dif-
ferent modalities of therapy, showed by median survival
are very uncommon.
In our patient head MR images showed multiple me-
tastases particularly in the left hemisphere of the brain.
The irradiation therapy on the whole CNS was per-
formed – 30 Gy/10 fractions. For the next few weeks her
condition was well. After that period, in July 2005 she be-
came irreparable worse. She needed constantly assis-
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tance for all the activities of daily living. It was clearly
understood that she had to have another chemotherapy,
carboplatin and cyclopfosphamid, but because of the
thrombocytopenia, the chemotherapy was delayed.
The patient died in July, 2005, with hepatorenal in-
sufficient and lack of the consciousness.
The median follow-up period for brain metastases was
8.5 months, range 5–19 months8. Because of bed general
condition of our patient and according to her years, we de-
cided our patient treated by irradiation on whole CNS. Af-
ter such therapy, she lived for next 3 months. It has to be
emphasized that she was in bed general condition because
of what neurosurgeon and oncologist were against any
radical treatments on brain metastases. She was also un-
able to receive any other chemotherapy, so irradiation was
the only acceptable palliative therapy.
In conclusion, this case of laboratory and histopa-
thologicaly confirmed paraneoplastic cerebellar degener-
ation and brain metastases in a patient with epithelial
ovarian cancer are uncommon in medical literature. Ac-
cording to all today’s medical knowledge, first she under-
went surgical treatment, than chemotherapy and irradi-
ation therapy on the whole CNS and physical therapy.
From the appearance of the first neurological signs and
death, treated her by all the procedure mentioned above,
passed about 3 years, and that is data that other authors
mention talking about the disease-free interval for ovar-
ian cancer8,9.
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RAK JAJNIKA: PCD I METASTAZE U MOZGU
S A @ E T A K
Paraneoplasti~na cerebelarna degeneracija (PCD) naj~e{}a je manifestacija paraneoplasti~nog sindroma, koji se mo`e
se javiti uz mnoge malignome, no naj~e{}e ide uz rak plu}a, jajnika i dojke. Sindrom je povezan s rakom, ali nije uzro-
kovan samim rakom ni njegovim presadnicama. Patohistolo{ki, nalazi se gubitak Purkinjeovih stanica u malom mozgu.
Imunolo{kim metodama registrira se postojanje autoantitijela na Purkinjeove stanice. Klini~ki, dolazi do subakutnog
razvoja neurolo{ke simptomatologije. Neurolo{ki simptomi nerijetko se mogu javiti uz ostale uredne klini~ke poka-
zatelje, pa se tek dijagnosti~kom laparoskopijom, odnosno eksplorativnom laparotomijom, potom i patohistolo{kom
obradom materijala, mo`e dokazati postojanje raka. Nakon lije~enja kemoterapeuticima i imunoglobulinima, neuro-
lo{ki se status bolesnika stabilizira, me|utim ubrzo nastupi daljnje pogor{anje. Letalni ishod bolesti obi~no nastupi 3-5
godina nakon pojave prvih znakova paraneoplasti~nog sindroma. Opisan je slu~aj 63-godi{nje bolesnice s PCD-om kao
prvom manifestacijom bolesti. U bolesnice su se razvile metastaze u mozgu i letalni je ishod nastupio gotovo 3 godine
nakon pojave prvih simptoma PCD-a.
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